Why do charities need to keep funding research into leukemia and blood cancer in general?
Managing transplant ineligible AML patients
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
Clinical implications of persisting preleukemic clones in remission in acute myeloid leukemia (AML)
Stephan Grupp discussing his work at the University of Pennsylvania